In patients with systemic lupus erythematosus (SLE), reduction or discontinuation of hydroxychloroquine (HCQ) is associated with a 2-fold increased risk for flares, even during remission.
Flare risk was found to be higher with HCQ reduction (HR, 1.13; 95% CI, 0.98-1.30) and discontinuation (HR, 1.41; 95% CI, 1.19-1.67) compared with HCQ maintenance.
Estimated reasons for HCQ reduction included American Academy of Ophthalmology guidelines (5%) and low disease activity (55%). Reasons for HCQ discontinuation included retinal changes (4%) and clinical remission (15%). The remainder of patients in each cohort reduced or discontinued HCQ for other reasons, including intolerance or patient preference
Read More: Brasil C, Hanly J, Urowitz M, et al. Impact of systemic lupus disease activity state on flare risk after hydroxychloroquine maintenance, reduction or discontinuation in a multinational inception cohort. Presented at: ACR Convergence 2021; November 3-10, 2021. Abstract 0959